Medtronic has received the CE mark for its CoreValve system, used for direct aortic and subclavian transcatheter aortic valve implantation in patients with severe aortic stenosis.
This direct treatment option is designed to provide aortic stenosis patients with an alternative therapy to the transfemoral, transapical and subclavian artery approaches.
Earlier studies showed that the direct aortic approach demonstrates high procedural success rates and overall survival rates.
The new treatment will allow for easier manipulation and placing of the valve because of the short distance from access site to implantation site.
Currently, the Medtronic CoreValve system is limited to investigational use in the US.